Fiduciary Group LLC Reduces Holdings in GSK plc (NYSE:GSK)

Fiduciary Group LLC lowered its holdings in GSK plc (NYSE:GSK) by 38.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 5,801 shares of the pharmaceutical company’s stock after selling 3,566 shares during the quarter. Fiduciary Group LLC’s holdings in GSK were worth $215,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. FMR LLC lifted its holdings in GSK by 7.7% in the 3rd quarter. FMR LLC now owns 18,099,513 shares of the pharmaceutical company’s stock worth $656,107,000 after buying an additional 1,291,161 shares during the period. Primecap Management Co. CA lifted its holdings in GSK by 2.4% in the 3rd quarter. Primecap Management Co. CA now owns 12,058,770 shares of the pharmaceutical company’s stock worth $437,130,000 after buying an additional 287,000 shares during the period. Royal Bank of Canada lifted its holdings in GSK by 5.1% in the 3rd quarter. Royal Bank of Canada now owns 8,079,897 shares of the pharmaceutical company’s stock worth $292,896,000 after buying an additional 389,871 shares during the period. Morgan Stanley lifted its holdings in GSK by 2.1% in the 3rd quarter. Morgan Stanley now owns 7,551,555 shares of the pharmaceutical company’s stock worth $273,744,000 after buying an additional 156,480 shares during the period. Finally, Provident Trust Co. lifted its holdings in GSK by 53.6% in the 4th quarter. Provident Trust Co. now owns 3,716,830 shares of the pharmaceutical company’s stock worth $137,746,000 after buying an additional 1,297,385 shares during the period. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on GSK. Jefferies Financial Group raised GSK from a “hold” rating to a “buy” rating in a research report on Wednesday, January 3rd. Guggenheim raised GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. Citigroup raised GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. Finally, Morgan Stanley initiated coverage on GSK in a research report on Tuesday, January 23rd. They set an “equal weight” rating for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

GSK Stock Performance

Shares of GSK opened at $41.63 on Tuesday. The business’s fifty day simple moving average is $41.82 and its two-hundred day simple moving average is $39.01. The company has a current ratio of 0.88, a quick ratio of 0.62 and a debt-to-equity ratio of 1.19. GSK plc has a 12 month low of $33.33 and a 12 month high of $43.84. The company has a market cap of $86.28 billion, a price-to-earnings ratio of 13.83, a P/E/G ratio of 1.44 and a beta of 0.64.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.04). GSK had a net margin of 16.24% and a return on equity of 51.45%. The business had revenue of $10 billion for the quarter, compared to analysts’ expectations of $9.79 billion. Research analysts anticipate that GSK plc will post 4.03 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, April 11th. Stockholders of record on Friday, February 23rd were paid a $0.3564 dividend. This is an increase from GSK’s previous quarterly dividend of $0.34. This represents a $1.43 dividend on an annualized basis and a dividend yield of 3.42%. The ex-dividend date of this dividend was Thursday, February 22nd. GSK’s dividend payout ratio (DPR) is 52.82%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.